JavaScript NENÍ povolen !

* Zobrazit nápovědu

3 záznamů v Medvik Filtry

Článek

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Donnelly, J Peter
Autor Donnelly, J Peter Department of Hematology, Radboudumc, Nijmegen, The Netherlands
Chen, Sharon C
Autor Chen, Sharon C Centre for Infectious Diseases and Microbiology, Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, University of Sydney, Sydney, Australia
Kauffman, Carol A
Autor Kauffman, Carol A Division of Infectious Diseases, University of Michigan, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA
Steinbach, William J
Autor Steinbach, William J Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
Baddley, John W
Autor Baddley, John W Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA
Verweij, Paul E
Autor Verweij, Paul E Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands
Clancy, Cornelius J
Autor Clancy, Cornelius J University of Pittsburgh, Pittsburg, Pennsylvania, USA
Wingard, John R
Autor Wingard, John R Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
Lockhart, Shawn R
Autor Lockhart, Shawn R Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Groll, Andreas H
Autor Groll, Andreas H Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology University Children's Hospital, Münster, Germany

Clinical infectious diseases. 2020 ; 71 (6) : 1367-1376. [pub] 20200912

Clin Infect Dis
ISSN 1537-6591
Medvik
Zdroj

BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.